Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 13,740 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 48
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more

Conditions: HIV Prevention
Interventions: Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen; Drug · Radiation
Lead sponsor: Ian McGowan; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: LY2452473, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 19 Years and older · Male only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Gainesville, Florida • Baltimore, Maryland • Boston, Massachusetts

Conditions: Chronic Migraine
Interventions: Xeomin, Placebo; Drug
Lead sponsor: Merz Therapeutics GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 48
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 42 more

Conditions: Food Allergy
Interventions: Egg Oral Immunotherapy, Baked Egg; Drug
Lead sponsor: Hugh A Sampson, MD; Other
Eligibility: 3 Years to 16 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 5
States / cities: Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Amblyopia
Interventions: Luminopia, Eye Patch; Device · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 4 Years to 7 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 72
States / cities: Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 58 more

Conditions: Pancreatic Cancer
Interventions: Pancreatic Duct Stent Placement; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neuroendocrine Tumors
Interventions: 177Lu-DOTA0-Tyr3-Octreotate; Drug
Lead sponsor: Advanced Accelerator Applications; Industry
Eligibility: 18 Years and older
U.S. locations: 41
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 33 more

Conditions: Cystic Fibrosis
Interventions: VX-561, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 30
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 25 more

Conditions: Systemic Lupus Erythematosus
Interventions: GSK2586184 standard formulation, Simvastatin, Rosuvastatin, GSK2586184 new formulation; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glaucoma
Interventions: Latanoprost (0.005%); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 30 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions: Tulmimetostat, Enzalutamide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 22
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 15 more

Conditions: Cardiovascular Disease
Interventions: bococizumab (PF-04950615), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 10,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 518
States / cities: Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more

Conditions: Asthma
Interventions: Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 148
States / cities: Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more

Conditions: Prostatic Neoplasms, Prostate Cancer, Cancer of the Prostate
Interventions: High-resolution ultrasound guided prostate biopsy, Standard ultrasound guided prostate biopsy; Device
Lead sponsor: Exact Imaging; Industry
Eligibility: 40 Years to 79 Years · Male only
Enrollment: 1,676 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Baltimore, Maryland • Virginia Beach, Virginia

Conditions: Hepatitis C Virus Infection
Interventions: Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 8
States / cities: Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more

Conditions: Gastroesophageal Reflux
Interventions: Nissen fundoplication; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: Up to 24 Months
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Retinitis Pigmentosa
Interventions: Argus II; Device
Lead sponsor: University of California, Santa Barbara; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Santa Barbara, California • Baltimore, Maryland • Ann Arbor, Michigan

Conditions: Acute Myocardial Infarction (AMI), Coronary Occlusion, Acute Coronary Syndrome
Interventions: Guardian System; Device
Lead sponsor: Angel Medical Systems; Industry
Eligibility: 21 Years and older
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 95
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 85 more

Conditions: Prostate Cancer
Interventions: ExoDx Prostate; Diagnostic Test
Lead sponsor: Exosome Diagnostics, Inc.; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Baltimore, Maryland • Voorhees Township, New Jersey

Conditions: Paramyxoviridae Infections, Virus Diseases
Interventions: rHPIV3cp45, rHPIV3cp45 placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 36 Months
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: HIV Infections, Pregnancy
Interventions: Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 2,009 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 19
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more

Conditions: Blood Coagulation Disorders, Acute Major Bleeding
Interventions: Beriplex® P/N (Kcentra), Fresh frozen plasma; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • San Franciso, California + 33 more

Conditions: Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
Interventions: BCG TICE Vaccine; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy

Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184

Optic Nerve Head Strain in Non-glaucoma Subjects

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

Clinical Trial Comparing Open and Laparoscopic Nissen Fundoplication in Children

The Perceptual Experience of Argus II Users

AngelMed for Early Recognition and Treatment of STEMI

ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting

Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children

A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections